Daily non-political popular news in brief.

After 2 years, study shows Revlimid patients live longer and remain transfusion free

Dr. Alan List, from the H. Lee Moffitt Cancer Center & Research Institute, presented the final results from a pivotal Phase II trial evaluating Revlimid in patients with an incurable blood cancer known as myelodysplastic syndromes (MDS) at this year's American Society of Hematology (ASH) meeting.

Read more »

Keywords: study, shows, revlimid, patients, live, longer, remain, transfusion, free, show, patient

« Previous | Next »

Similar news on "After 2 years, study shows Revlimid patients live longer and remain transfusion free":

1. Aggressive therapy best for certain AML patients
   08-01-2007 · EurekAlert!
   A new study suggests that acute leukemia patients whose cancer cells show a genetic change that usually predicts a swift return of the disease following remission may remain disease-free longer when given aggressive therapy. The findings apply to people with acute myeloid leukemia whose cancer cells have normal-looking chromosomes and a gene mutation called MLL-PTD.
   Similar news · Read more »
   
2. Older patients with major depression live longer with appropriate treatment, Penn study shows
   05-14-2007 · EurekAlert!
   Older patients with major depression whose primary care physicians team with depression care managers are 45 percent less likely to die within a five-year time period than older adults with major depression who receive their care in primary care practices where there are no depression care managers. This study, conducted by researchers at the University of Pennsylvania School of Medicine, appears in the current issue of the Annals of Internal Medicine.
   Similar news · Read more »
   
3. University of Colorado study shows intensive therapy helps in battle against bipolar disorder
   04-02-2007 · EurekAlert!
   New results from the largest federally funded bipolar study ever conducted show that patients who receive psychotherapy in addition to medication get better faster from bipolar disorder's debilitating depression and stay better longer, according to a University of Colorado at Boulder researcher involved in the study.
   Similar news · Read more »
   
4. Cetuximab may prolong survival for head and neck cancer patients
   01-18-2007 · EurekAlert!
   Preliminary findings show adding the chemotherapy drug cetuximab (brand name Erbitux) to radiation therapy and chemotherapy may help some patients with head and neck cancer live longer, according to a study presented at the plenary session of the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
   Similar news · Read more »
   
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
   06-02-2007 · EurekAlert!
   The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).
   Similar news · Read more »
   
6. From clinical cancer research: rethinking therapeutic cancer vaccine trials
   07-03-2007 · EurekAlert!
   Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, a team of National Cancer Institute researchers asks a fundamental question: are we looking at cancer vaccine trials the wrong way?
   Similar news · Read more »
   
7. Research shows survival benefit for leukemia patients treated with arsenic trioxide
   06-04-2007 · EurekAlert!
   Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
   Similar news · Read more »
   
8. Provider influence and patient barriers affect use of colorectal cancer screening
   02-11-2008 · EurekAlert!
   A new study shows that health care providers play a key role in the likelihood their patients are screened for colorectal cancer.
   Similar news · Read more »
   
9. New drug shows promise for treating epileptic seizures
   04-05-2007 · EurekAlert!
   A new study appearing in the latest issue of Epilepsia shows that a new drug called Eslicarbazepine (ESL) shows promise as a treatment for epilepsy patients whose symptoms remain uncontrolled with existing medications. A once-daily dose was shown to be most effective, offering patients added convenience as current treatments can involve several doses per day.
   Similar news · Read more »
   
10. Novel MS drug shows promise in 2 lethal leukemias
    08-28-2007 · EurekAlert!
    A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia. The laboratory and animal study focused on the drug, called fingolimod. Researchers said it might help patients with advanced chronic myelogenous leukemia or acute lymphocytic leukemia, and whose cancer cells show a particular genetic change called the Philadelphia chromosome.
    Similar news · Read more »